New guidelines from the National Comprehensive Cancer Network regarding cardiac toxicity for patients with cancer or cancer survivors should have cancer institutions talking about how to implement cardiac follow-up for patients, said Crystal S. Denlinger, of FOx Chase Cancer Center.
New guidelines from the National Comprehensive Cancer Network regarding cardiac toxicity for patients with cancer or cancer survivors should have cancer institutions talking about how to implement cardiac follow-up for patients, said Crystal S. Denlinger, of FOx Chase Cancer Center.
Transcript (slightly modified)
How does Fox Chase Cancer Center follow-up on potential cardiac toxicity for patients with cancer and cancer survivors?
We don't have a defined cardio-oncology follow-up program; we have cardiologists who are interested in cardio-oncology who are people we routinely refer our cardiac patients or patients who have concerns about heart disease to this group. With the unveiling of the new guideline [from that National Comprehensive Cancer Network] there is certainly a lot more talk at Fox Chase about developing some algorithm or some programmatic pathway that could potentially result in a more structured program.
I think every institution has different resources and different needs. At our institution, our cardiology group is an affiliated practice, not necessarily housed within Fox Chase, and so we use them to take care of our patients where cardiac diseases are either found or where they may be at risk for cardiac diseases. So it's not a formal program, but there is infrastructure within Fox Chase for patients who have cardiac needs after treatment or on treatment.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Redefining Long COVID Care With Personalized Treatment
March 20th 2025To mark the 5-year anniversary of the COVID pandemic, The American Journal of Managed Care® spoke with Noah Greenspan, DPT, PT, CCS, EMT-B, cardiopulmonary physical therapist and director of the Pulmonary Wellness and Rehabilitation Center in New York City.
Read More
STEER Data Open Door to SMA Gene Therapy for Wider Age Range of Children
March 19th 2025Delivery of onasemnogene abeparvovec into the intrathecal space was safe and effective for children with spinal muscular atrophy (SMA) aged 2 to 17 years, who had previously been shut out of receiving gene therapy.
Read More